Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CS-3150

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BACKGROUND AND OBJECTIVES The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2019
2019
Mineralocorticoid receptors (MRs) are implicated in the pathology of hypertension. MR blockers are recommended for the treatment… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2019
2019
Although beneficial antihypertensive and antialbuminuric effects of steroidal mineralocorticoid receptor (MR) antagonists have… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2019
2019
This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label comparator study to investigate the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
2019
2019
Esaxerenone (CS-3150) is a novel, nonsteroidal, selective mineralocorticoid receptor blocker. The absorption, metabolism… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2018
2018
Herein, we studied the effects of the novel nonsteroidal selective mineralocorticoid receptor (MR) blocker, esaxerenone, on blood… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2018
2018
Objective: ESAX-HTN study is a randomized, double-blind phase III study of esaxerenone (CS-3150), a novel non-steroidal… Expand
2016
2016
The present study was designed to assess both preventive and therapeutic effects of (S)-1-(2-Hydroxyethyl)-4-methyl-N-[4… Expand
2015
2015
The present study was designed to characterize the pharmacological profile of CS-3150, a novel non-steroidal mineralocorticoid… Expand
2015
2015
The present study was designed to evaluate the antihypertensive and cardiorenal protective effects of CS-3150, a novel non… Expand